Close Menu

NEW YORK (GenomeWeb) – GenomeDx said today that it has signed an agreement to test its Decipher GRID database of cancer genomic profiles with samples from prostate cancer clinical trials run by Janssen Pharmaceuticals.

Under the terms of the deal, GenomeDx will test the samples in order to evaluate the association of prognostic and predictive genomic signatures from the Decipher GRID platform — which includes more than 40,000 RNA expression profiles of urologic cancers — with clinical outcomes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.